HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis

Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes. Objectives: This study aimed to evaluate the cost-effectiveness o...

Full description

Saved in:
Bibliographic Details
Main Authors: Mingjun Rui, Yingcheng Wang, Qiran Wei, Joyce H. S. You
Format: Article
Language:English
Published: SAGE Publishing 2025-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251356109
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items